Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Second Look Laparoscopy in Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Procedure: LaparoscopyProcedure: peritonectomyDrug: Folinic AcidDrug: 5-FluorouracilDrug: OxaliplatinDrug: systemic chemotherapy
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 140
- Registration Number
- NCT01628211
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori , Oncologia Medica - Dipartimento Entero-proctologico, Napoli, Italy
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT01593020
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2016-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 123
- Registration Number
- NCT01590719
Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer
- Conditions
- Gastric Adenocarcinoma
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Target Recruit Count
- 39
- Registration Number
- NCT01567618
- Locations
- 🇨🇳
Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer
- Conditions
- Head and Neck Neoplasms
- Interventions
- Drug: paclitaxel albumin-stabilized nanoparticle formulationDrug: CisplatinDrug: FluorouracilRadiation: Intensity modulated radiation therapyDrug: CetuximabProcedure: Quality-of-life assessment
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 30
- Registration Number
- NCT01566435
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
- Conditions
- Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the StomachSquamous Cell Carcinoma of the EsophagusStage II Esophageal CancerStage II Gastric CancerStage III Esophageal CancerStage III Gastric Cancer
- Interventions
- Drug: erlotinib hydrochlorideDrug: oxaliplatinDrug: fluorouracilRadiation: radiation therapyProcedure: conventional surgeryOther: immunohistochemistry staining methodProcedure: positron emission tomographyProcedure: computed tomographyProcedure: laboratory biomarker analysisGenetic: gene expression analysisRadiation: fludeoxyglucose F 18
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 9
- Registration Number
- NCT01561014
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT01560949
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients
- Conditions
- Rectal Adenocarcinoma
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Target Recruit Count
- 25
- Registration Number
- NCT01554059
- Locations
- 🇨🇳
Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
- Conditions
- Extrahepatic Bile Duct CancerNauseaVomitingStage II Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic Cancer
- Interventions
- Drug: aprepitantDrug: gemcitabine hydrochlorideDrug: capecitabineDrug: fluorouracilProcedure: radiation therapyOther: questionnaire administrationProcedure: quality-of-life assessmentProcedure: nausea and vomiting therapyProcedure: management of therapy complications
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 22
- Registration Number
- NCT01534637
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 51
- Registration Number
- NCT01529164
- Locations
- 🇨🇳
Cancer hospital & Institute,Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.